Phase II single arm study testing SBRT, Adenosine signaling Modulation (AB680, AB928), and Immune Checkpoint inhibition (AB122) for men with hormone sensitive Oligometastatic prostate cancer (SBRT-AMICO)

This study aims to test the safety and effectiveness of zimberelimab, etrumadenant, and quemliclustat when given together with radiotherapy as a potential treatment to hormone sensitive oligometastatic (cancer that has spread to other areas of the body) prostate cancer. Zimberelimab, etrumadenant, and quemliclustat are considered immunotherapy drugs. These type of drug works by blocking a protein that can cause tumors to grow. By blocking this protein, the study drugs may cause your cancer to stop growing or to shrink. These study drugs are not approved by Health Authorities including the United States Food and Drug Administration (FDA) for the treatment of prostate cancer. Patients with the type of cancer you have usually receive radiotherapy. Radiotherapy is a treatment that delivers radiation to your tumor, while sparing normal surrounding tissues. As a part of this study, you will receive radiotherapy to active prostate cancer located beyond your prostate.

Are you Eligible? (Inclusion Criteria)

• Have you been diagnosed with hormone sensitive oligometastatic prostate cancer and previously received treatment (surgery or radiotherapy)? - Have you not been exposed to androgen deprivation therapy (ADT) within the last 6 months? - Are you aged 18 years or older? - Are you able to swallow medications?